Meet Maverex in Vienna at ISPOR Europe 2026
8–11 November 2026 | Vienna, Austria | Stand 711, Level -2, Hall X2
A chance to connect
The Maverex team will be at ISPOR Europe 2026 from 8–11 November. See who's attending below and book a time to talk with any of us.
We’re also presenting our research, including a podium presentation:
Estimating Greenhouse Gas Emissions Avoided Through HPV Vaccination in Cervical Cancer and CIN3 Care Pathways
Monday 9 November, 10:30–11:30 CET | Room TBC | Presented by Cheryl Jones, Head of Environmental Modelling
We look forward to seeing you there!
See who’s attending and book a meeting
Our research schedule at ISPOR Europe 2026
We’re presenting eight posters and one podium presentation at ISPOR Europe 2026, covering topics across HEOR and market access.
Podium Presentation
Room TBC | Monday 9 November, 10:30–11:30 CET
Estimating Greenhouse Gas Emissions Avoided Through HPV Vaccination in Cervical Cancer and CIN3 Care Pathways
Presented by: Cheryl Jones
Poster Presentations
Poster Session 1 | Monday 9 November, 10:30–13:30 CET
Transportability Methods for RWE – HTA Acceptability and Methodological Guidance - HTA43
Presented by: Anne Wilson
How Immature Is Too Immature? OS Data Trends in NICE HTA Submissions - CO30
Presented by: Steph Stephens
Poster Session 2 | Monday 9 November, 16:00–19:00 CET
Modelling Patient Travel in Environmental Sustainability Assessments of Care Pathways: Methodological Solutions for Data-Scarce Settings - MSR76
Presented by: Cheryl Jones
Why Is Environmental Sustainability Evidence Difficult to Identify? A Bibliometric Analysis Reveals Gaps in Indexing, Database Coverage, and Publication Coverage - MSR117
Presented by: Nick Pooley
Payer and Regulator Evidence Requirements for Clinical Outcome Assessments: A Comparative Review of US, English, European and Canadian Guidance - MSR119
Presented by: Rhiannon Chan
Poster Session 3 | Tuesday 10 November, 10:30–13:30 CET
When Does Environmental Impact Add Value to Cost-Utility Analysis? A Proof-of-Concept Application in Severe Asthma Biologics - PT23
Selected for Poster Tour, presented by: Steph Stephens
Poster Session 5 | Wednesday 11 November, 9:00–11:30 CET
Pipeline Review of Traditional Small Molecule Antibacterial Medicines - HPR226
Presented by: Nick Pooley
Trends and Drivers in Cancer Drugs Fund Use in Non-Small Cell Lung Cancer - HTA342
Presented by: Lizzie Adkins
.
-
Connect
Members of the Maverex Team are on hand to help answer your questions and queries at the stand. They’re just some of our dedicated team, why not meet the rest?
-
Discover
Our specialised cross-functional teams work across all market access needs. From Evidence Generation to Economic and Environmental Modelling, explore our full range of services.
-
Explore
Our customers value the services and high-quality deliverables we provide, and they continue to work with us again and again. Explore some of our recent publications.
Keep the conversation going
There’s much more to Maverex
Maverex is global market access consultancy with over 35 highly-skilled professionals specialising in health economics, statistics, epidemiology, environmental modelling, and market access, and a shared commitment to environmental responsibility. Our team thrives on collaboration, fostering a culture of innovation, support, and problem-solving through continuous learning and the sharing of expertise. Known for our scientific rigor, responsiveness, and high-quality deliverables, our customers value the services we provide, and they continue to work with us again and again.
Recent feedback
